NDAORAL-21TABLET
Approved
Nov 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+80 21-DAY is an oral combination oral contraceptive containing mestranol (estrogen) and norethindrone (progestin) in a 21-day cyclic tablet regimen. It prevents ovulation and alters cervical mucus to prevent pregnancy. This product represents a foundational generation of hormonal contraceptives developed in the late 1960s.
LOE Approaching
As a legacy contraceptive approaching LOE with moderate competitive pressure (30), commercial teams are likely downsizing or consolidating this product into combination portfolios.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORINYL 1+80 offers limited career growth potential given its LOE-approaching status and zero linked job openings. Professionals on this team are typically managing decline, optimizing manufacturing costs, and planning transition strategies rather than pursuing innovation or market expansion.
Brand ManagerField Sales Representative
Worked on NORINYL 1+80 21-DAY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.